GIP

GIP

Gastric inhibitory polypeptide (GIP) is a hormone that is released from the K cells in the duodenum of the small intestine in response to ingested fat. Its primary function is to stimulate the release of insulin from pancreatic β-cells in response to glucose, thereby limiting postprandial hyperglycemia. GIP works in conjunction with GLP-1 to potentiate glucose-dependent insulin secretion.From: The Healthy Indoor Environment [2019], Effect of 6 weeks of very low-volume high-intensity interval training on oral glucose-stimulated incretin hormone response [2022], Reversibility of Chronic Disease and Hypersensitivity,Volume 2 [2019]

Diabetes Mellitus/Anti-DM Pharmacological Management

View Chapter

Purchase Book

Published in Mihai V. Putz, New Frontiers in Nanochemistry, 2020

Bogdan Bumbăcilă, Corina Duda-Seiman, Daniel Duda-Seiman, Mihai V. Putz

Analogs of the incretins Glucagon-like peptide-1 (GLP-1), and Glucose-dependent insulinotropic peptide (GIP) have been developed to treat type 2 diabetes mellitus. They are protease resistant and have a longer biological half-life than the native peptides (Holscher, 2010).

Effect of 6 weeks of very low-volume high-intensity interval training on oral glucose-stimulated incretin hormone response

View Article

Journal Information

Published in European Journal of Sport Science, 2022

Morten Hindsø, Anja Birk Kuhlman, Tine Lovsø Dohlmann, Michael Taulo Lund, Bolette Hartmann, Jens Juul Holst, Steen Larsen, Jørn Wulff Helge

GLP-1 and GIP are released from the small intestine in response to food ingestion and among other functions limit postprandial hyperglycemia through potentiation of glucose-dependent insulin secretion from pancreatic β-cells (Holst, 2019). GLP-1 also affects postprandial glucose concentrations through inhibitory effects on gastric emptying rate and glucagon secretion from pancreatic α-cells, whereas GIP under certain circumstances stimulates glucagon secretion (Holst, 2019).

Explore chapters and articles related to this topic

Diabetes Mellitus/Anti-DM Pharmacological Management

Effect of 6 weeks of very low-volume high-intensity interval training on oral glucose-stimulated incretin hormone response